Is actemra safe for patients with a history of diverticulitis?

What safety data exists for Actemra in patients with prior diverticulitis?

Actemra (tocilizumab) carries a boxed warning for serious infections, including gastrointestinal perforations. Patients with a history of diverticulitis may face higher risk of intestinal perforation while taking the drug. The prescribing information recommends avoiding Actemra in patients with active or recent diverticulitis. Clinical trials and post-marketing reports link tocilizumab to GI perforations, often in patients with history of diverticulitis or concomitant steroid use. [1]

What happens if a patient with past diverticulitis takes Actemra?

Patients who already have scar tissue from healed diverticulitis can develop silent perforations without classic symptoms. Because tocilizumab suppresses inflammation, normal warning signs such as abdominal pain or fever may be masked. This can delay diagnosis and ergonize treatment. Post-marketing surveillance shows GI perforations occur more frequently than expected in patients with this history. [1]

How does the manufacturer warn doctors about this risk?

The prescribing information instructs clinicians to evaluate patients for latent tuberculosis, hepatitis, and GI perforation risk before starting Actemra. It tells doctors to educate patients on symptoms of perforation and to monitor closely after start. The company advises immediate discontinuation if perforation occurs. [1]

Why are companies challenging this patent?

No, the question does not relate to competing manufacturers or patent disputes. The query focuses on clinical safety rather than intellectual property. [2]

When does exclusivity expire?

No, the question does not relate to exclusivity timelines. The focus is on patient safety with history of diverticulitis. [2]

When does the Actemra patent expire?

The Actemra patent expires in 2023, but generics and biosimilars are already available in some markets. [2